|Bid||85.83 x 1200|
|Ask||87.33 x 800|
|Day's Range||85.09 - 86.64|
|52 Week Range||69.36 - 94.85|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||19.89|
|Forward Dividend & Yield||1.60 (1.84%)|
|1y Target Est||N/A|
Solid global demand, substantial impact from the electron microscopy business and robust volume growth and productivity are likely to favor Thermo Fisher's (TMO) analytical instruments revenues.
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner's (CERN) Q2 earnings. However, expected decline in bookings is likely to be a dampener.
Probable revenue growth in APAC and EMEA regions and higher Oncology revenues are likely to aid Varian Medical (VAR) in Q3 earnings. However, contraction in margins might be a dampener.
Cadence Design (CDNS) gains from strong adoption of it's digital and signoff, custom and analog, IP solutions and expanding customer base.
Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.
Zacks.com featured highlights include: Oracle, AngloGold Ashanti, AmerisourceBergen, Ford Motor and CACI International
Skyworks (SWKS) is expected to get hurt by softness in Chinese market. Moreover, unit decline across mobile business is likely to impact the third-quarter results.
AmerisourceBergen (ABC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Top-line growth and better-than-expected segmental performance are likely to aid McKesson (MCK) in Q1. However, rise in adjusted operating expenses is likely to be a dampener.
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.
Shares of drug distributors and pharmacy-benefit-manager owners got a boost on Thursday after the Trump administration said it would be withdrawing its plan to overhaul the rebates that drugmakers give to middlemen in Medicare.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.